Patients with poorly controlled diabetes face higher risk than those achieving target HbA1c levels, emphasising the importance of optimal glycaemic management
Increased glucose intolerance related to digoxin treatment in patients with type 2 diabetes mellitus
Pre-clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis
Like most telehealth GLP-1 platforms, BrightMeds does not proactively publish Certificate of Analysis documents for its medication batches
Patients using GLP-1 medications alongside insulin or sulfonylureas (e.g., glipizide, glimepiride, glyburide) face an increased risk of hypoglycemia
The risk profile is similar for both medications, but individual sensitivity varies